# EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors

> **NCT07410676** · PHASE1,PHASE2 · RECRUITING · sponsor: **Essen Biotech** · enrollment: 83 (estimated)

## Conditions studied

- Cancer
- Sarcoma
- Leukaemia
- Breast Cancer (Locally Advanced or Metastatic)
- Lung Cancer (Diagnosis)
- Colorectal Cancer
- Melanoma (Skin Cancer)
- Bladder Cancer
- Kidney Cancer
- Pancreatic Cancer Metastatic
- Liver Cancer (Primary and Metastatic)
- Ovarian Cancer
- Esophageal Cancer
- Glioblastoma
- Non-Melanoma Skin Cancer

## Interventions

- **BIOLOGICAL:** EBNK-001 + IL-15 + Pembrolizumab

## Key facts

- **NCT ID:** NCT07410676
- **Lead sponsor:** Essen Biotech
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2028-12-21
- **Final completion:** 2029-12-21
- **Target enrollment:** 83 (ESTIMATED)
- **Last updated:** 2026-02-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07410676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07410676, "EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07410676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*